Briacell Therapeutics (BCT) Trading Down 7.4%

Share on StockTwits

Briacell Therapeutics Corp (CVE:BCT) traded down 7.4% during trading on Wednesday . The company traded as low as C$0.13 and last traded at C$0.13. 760,425 shares were traded during mid-day trading, an increase of 101% from the average session volume of 378,188 shares. The stock had previously closed at C$0.14.

The company has a quick ratio of 0.85, a current ratio of 0.96 and a debt-to-equity ratio of 228.18. The stock has a market cap of $19.42 million and a P/E ratio of -2.68.

Briacell Therapeutics (CVE:BCT) last posted its earnings results on Thursday, March 28th. The company reported C($0.01) EPS for the quarter.

ILLEGAL ACTIVITY NOTICE: “Briacell Therapeutics (BCT) Trading Down 7.4%” was reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this piece on another domain, it was copied illegally and republished in violation of United States & international copyright & trademark law. The correct version of this piece can be accessed at https://www.tickerreport.com/banking-finance/4272427/briacell-therapeutics-bct-trading-down-7-4.html.

Briacell Therapeutics Company Profile (CVE:BCT)

BriaCell Therapeutics Corp., an immuno-oncology focused biotechnology company, engages in developing personalized treatments for cancer. Its lead product candidate, Bria-IMT, is being tested in a clinical trial in combination with pembrolizumab (KEYTRUDA; manufactured by Merck & Co, Inc) in patients with advanced breast cancer.

See Also: Average Daily Trade Volume – What It Means In Stock Trading

Receive News & Ratings for Briacell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Briacell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Research Analysts’ Recent Ratings Changes for Tabula Rasa HealthCare
Research Analysts’ Recent Ratings Changes for Tabula Rasa HealthCare
Turkcell Iletisim Hizmetleri A.S.  Upgraded to “Hold” by Zacks Investment Research
Turkcell Iletisim Hizmetleri A.S. Upgraded to “Hold” by Zacks Investment Research
DS Smith  Upgraded to “Hold” by Zacks Investment Research
DS Smith Upgraded to “Hold” by Zacks Investment Research
Contrasting Yelp  and Verb Technology
Contrasting Yelp and Verb Technology
Cardtronics  Rating Lowered to Sell at BidaskClub
Cardtronics Rating Lowered to Sell at BidaskClub
BidaskClub Downgrades Oxford Immunotec Global  to Sell
BidaskClub Downgrades Oxford Immunotec Global to Sell


© 2006-2019 Ticker Report